Keymed Bio-B releases 2026 interim financial results

Summary

Keymed Biosciences (02162.HK) reported a 2026 interim revenue of 617M RMB (+24% YoY) and a net profit turnaround to 1.218B RMB AASTOCKS News. The profit was primarily driven by a 1.68B RMB one-time gain from the Ouro Medicines deal . Notably, core product revenue grew 132% to 393M RMB, fueled by the commercialization of Stapokibart (Kangyueda®) .

Impact Analysis

So basically, don’t let the massive 1.2B RMB net profit distract you—it’s largely a ‘sugar high’ from a 1.68B RMB one-time asset sale and upfront payment . The real signal here is the 132% explosion in product revenue to 393M RMB . This is a massive ‘tell’ that their commercialization engine for Stapokibart is firing on all cylinders post-NRDL inclusion .

Market’s likely focused on the non-recurring nature of the profit, but I’d read this as a de-risking event. The $257M upfront payment provides a fortress balance sheet, meaning no dilutive financing is needed anytime soon . The interesting part isn’t just the cash; it’s the execution. Transitioning from a biotech lab to a firm generating real sales growth while maintaining a 74% gross margin is rare ST/HK/2162. I’m watching for margin expansion as Stapokibart scales further. The trade here is betting on the core business outgrowing the ‘one-off’ noise. If the market sells the ‘peak profit’ news, it’s a buying opportunity for a long-term commercial winner.